Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211Ar]astato-3-pyridinecarboxylate

Nuclear Medicine and Biology

Volumn 26, Issue 4, 1999, Pages 405-411

  Reist, Craig J ^a   Foulon, Catherine F ^a   Alston, Kevin ^a   Bigner, Darell D ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Astatine 211; EGFRvIII; Internalization; Monoclonal antibodies; Radioimmunotherapy

Indexed keywords

ASTATINE 211; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY L8A4; N SUCCINIMIDYL 5 ASTATO 3 PYRIDINECARBOXYLATE; PYRIDINE DERIVATIVE; REAGENT; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STABILITY; DRUG SYNTHESIS; HALOGENATION; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; DRUG STABILITY; HUMANS; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RADIOIMMUNOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION;

EID: 0032982673     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00120-6     Document Type: Article

References (32)

1. Aaij C., Tschroots W., Lindner L., Feltkamp T.E.W. The preparation of astatine labelled proteins. Int. J. Appl. Radiat. Isot. 26:1975;25-30.
2. Berei K. and Vasaros L. (1981) Organic chemistry of astatine. Hungarian Academy of Sciences. Report KFKI-1981-10, 8-9. Budapest, Hungary.
3. Bigner D.D., Brown M.T., Friedman A.H., Coleman R.E., Akabani G., Friedman H.S., Thorstad W.L., McLendon R.E., Bigner S.H., Zhao X.-G., Pegram C.N., Wikstrand C.J., Herndon J.E. II, Vick N.A., Paleologos N., Cokgor I., Zalutsky M.R. Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas Phase I trial results . J. Clin. Oncol. 16:1998;2202-2212.
4. 131I-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication Phase I trial results . Clin. Cancer Res. 2:1997;963-972.
5. Foulon C.F., Alston K.L., Zalutsky M.R. Synthesis and preliminary biological evaluation of 3-iodobenzoyl norbiotinamide and 5-iodo-3-pyridine acyl norbiotinamide Two radioiodinated biotin conjugates with improved stability . Bioconjugate Chem. 8:1997;179-186.
6. Foulon C.F., Alston K.L., Zalutsky M.R. Astatine-211 labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. Nucl. Med. Biol. 25:1998;81-88.
7. 2 fragment. Cancer Res. 50:1990;3514-3520.
8. Garg S., Garg P.K., Zalutsky M.R. N-Succinimidyl-5-(trialkylstannyl)-3-pyridine carboxylates A new class of reagents for protein radioiodination . Bioconjugate Chem. 2:1991;50-56.
9. Geissler F., Anderson S.K., Press O. Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. Cell Immunol. 137:1991;96-110.
10. Hall E. Radiobiology for the Radiobiologist. 3rd edn. 1988;Lippincott, Philiadelphia.
11. Humphrey P.A., Wong A.J., Vogelstein B., Zalutsky M.R., Fuller G.N., Archer G.E., Freidman H.S., Kwatra M.M., Bigner S.H., Bigner D.D. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl. Acad. Sci. USA. 87:1990;4207-4211.
12. Kampf G. Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol. Radiother. 29:1988;631-658.
13. 211At reaction. Appl. Radiat. Isot. 47:1996;135-143.
14. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P.A. Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods. 72:1984;77-89.
15. Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., Biegel J.A., Hayes R.L., Wong A.J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55:1995;5536-5539.
16. 125I-labeled amidobisphosphonates. Nucl. Med. Biol. 26:1999;397-403.
17. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., Huang H.J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA. 91:1994;7727-7731.
18. Novak-Hofer I., Amstutz H.P., Morgenthaler J.J., Schubiger P.A. Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells. Int. J. Cancer. 57:1994;427-432.
19. Press O.W., Farr A.G., Borroz K.I., Anderson S.K., Martin P.J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 49:1989;4906-4912.
20. Reist C.J., Archer G.E., Kurpad S.N., Wikstrand C.J., Vaidyanathan G., Willingham M.C., Moscatello D.K., Wong A.J., Bigner D.D., Zalutsky M.R. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies Use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts . Cancer Res. 55:1995;4375-4382.
21. Reist C.J., Archer G.E., Wikstrand C.J., Bigner D.D., Zalutsky M.R. Improved targeting of an anti-EGFRvIII monoclonal antibody in tumor xenografts after labeling using N-succinimdyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 57:1997;1510-1515.
22. Reist C.J., Batra S.K., Pegram C.N., Bigner D.D., Zalutsky M.R. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody Comparison with its murine parent . Nucl. Med. Biol. 24:1997;639-647.
23. Reist C.J., Garg P.K., Alston K.L., Bigner D.D., Zalutsky M.R. Radioiodinated of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 56:1996;4970-4977.
24. Vaughan A.T., Fremlin J.H. The preparation of astatine labelled proteins using an electrophilic reaction. Int. J. Nucl. Med. Biol. 5:1978;229-230.
25. Visser G., Diemer E., Kaspersen F. The nature of the astatine-protein bond. Int. J. Appl. Radiat. Isot. 32:1981;905-912.
26. Wikstrand C.J., Hale L.P., Batra S.K., Hill M.L., Humphrey P.A., Kurpad S.N., McLendon R.E., Moscatello D., Pegram C.N., Reist C.J., Traweek T., Wong A.J., Zalutsky M.R., Bigner D.D. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55:1995;3140-3148.
27. 2. Nucl. Med. Biol. 20:1993;917-927.
28. Zalutsky M., Narula A. Astatination of proteins using an N-succinimidyl tri-butylstannylbenzoate intermediate. Appl. Radiat. Isot. 39:1988;227-232.
29. Zalutsky M.R. Growth factor receptors as molecular targets for cancer diagnosis and therapy. Q. J. Nucl. Med. 41:1997;71-78.
30. Zalutsky M.R., Bigner D.D. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol. 35:1996;373-379.
31. 2 fragments with the alpha particle emitting nuclide astatine-211 Preservation of immunoreactivity and in vivo localizing capacity . Proc. Natl. Acad. Sci. USA. 86:1989;7149-7153.
32. Zalutsky M.R., Stabin M., Larsen R.H., Bigner D.D. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle emitting immunoconjugate. Nucl. Med. Biol. 24:1997;255-262.